Wall Street Backs Achieve Life Sciences: Cytisinicline Labeled 'Best-in-Class' Smoking Cessation Drug

Achieve Life Sciences gets Buy rating as its quit-smoking drug cytisinicline shows strong results; FDA decision due June 2026.